Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.48
KERX's Cash-to-Debt is ranked lower than
84% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. KERX: 0.48 )
Ranked among companies with meaningful Cash-to-Debt only.
KERX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.48  Med: No Debt Max: No Debt
Current: 0.48
0.48
No Debt
Equity-to-Asset -0.23
KERX's Equity-to-Asset is ranked lower than
94% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. KERX: -0.23 )
Ranked among companies with meaningful Equity-to-Asset only.
KERX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.23  Med: 0.78 Max: 0.93
Current: -0.23
-0.23
0.93
Debt-to-Equity -3.96
KERX's Debt-to-Equity is ranked lower than
99.99% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. KERX: -3.96 )
Ranked among companies with meaningful Debt-to-Equity only.
KERX' s Debt-to-Equity Range Over the Past 10 Years
Min: -15.07  Med: 1.57 Max: 13.95
Current: -3.96
-15.07
13.95
Debt-to-EBITDA -1.25
KERX's Debt-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. KERX: -1.25 )
Ranked among companies with meaningful Debt-to-EBITDA only.
KERX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.25  Med: -1.03 Max: -0.82
Current: -1.25
-1.25
-0.82
Piotroski F-Score: 3
Altman Z-Score: -10.50
Beneish M-Score: -1.23
WACC vs ROIC
20.18%
-543.79%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -143.59
KERX's Operating Margin % is ranked lower than
56% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. KERX: -143.59 )
Ranked among companies with meaningful Operating Margin % only.
KERX' s Operating Margin % Range Over the Past 10 Years
Min: -3978.25  Med: -623.8 Max: 38.97
Current: -143.59
-3978.25
38.97
Net Margin % -230.00
KERX's Net Margin % is ranked lower than
63% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. KERX: -230.00 )
Ranked among companies with meaningful Net Margin % only.
KERX' s Net Margin % Range Over the Past 10 Years
Min: -4121.67  Med: -615.03 Max: 41.62
Current: -230
-4121.67
41.62
ROA % -103.43
KERX's ROA % is ranked lower than
85% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. KERX: -103.43 )
Ranked among companies with meaningful ROA % only.
KERX' s ROA % Range Over the Past 10 Years
Min: -135.67  Med: -77.46 Max: 31.09
Current: -103.43
-135.67
31.09
ROC (Joel Greenblatt) % -795.69
KERX's ROC (Joel Greenblatt) % is ranked lower than
61% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. KERX: -795.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
KERX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -46369.35  Med: -7570.48 Max: 7114.49
Current: -795.69
-46369.35
7114.49
3-Year Revenue Growth Rate 64.50
KERX's 3-Year Revenue Growth Rate is ranked higher than
90% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. KERX: 64.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
KERX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -100 Max: 237.3
Current: 64.5
0
237.3
3-Year EBITDA Growth Rate 10.20
KERX's 3-Year EBITDA Growth Rate is ranked higher than
59% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. KERX: 10.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
KERX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -23.8 Max: 45.1
Current: 10.2
0
45.1
3-Year EPS without NRI Growth Rate -5.20
KERX's 3-Year EPS without NRI Growth Rate is ranked lower than
63% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. KERX: -5.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
KERX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -19.5 Max: 45.1
Current: -5.2
0
45.1
GuruFocus has detected 2 Warning Signs with Keryx Biopharmaceuticals Inc KERX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» KERX's 30-Y Financials

Financials (Next Earnings Date: 2018-07-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

KERX Guru Trades in Q2 2017

Joel Greenblatt 55,639 sh (New)
Steven Cohen 1,552,700 sh (+1452.70%)
Chuck Royce 256,725 sh (unchged)
Seth Klarman 25,791,678 sh (unchged)
David Abrams 5,719,176 sh (unchged)
» More
Q3 2017

KERX Guru Trades in Q3 2017

Chuck Royce 256,725 sh (unchged)
David Abrams 5,719,176 sh (unchged)
Seth Klarman 25,791,678 sh (unchged)
Joel Greenblatt 36,288 sh (-34.78%)
Steven Cohen 100,000 sh (-93.56%)
» More
Q4 2017

KERX Guru Trades in Q4 2017

David Abrams 9,719,176 sh (+69.94%)
Seth Klarman 25,791,678 sh (unchged)
Chuck Royce 256,725 sh (unchged)
Joel Greenblatt Sold Out
Steven Cohen Sold Out
» More
Q1 2018

KERX Guru Trades in Q1 2018

Seth Klarman 25,791,678 sh (unchged)
Chuck Royce 256,725 sh (unchged)
David Abrams 9,719,176 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with KERX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-12-31 Sold Out $4.39 - $7.95 $ 5.20-6%0
Joel Greenblatt 2017-09-30 Reduce -34.78%$6.35 - $8.25 $ 5.20-28%36,288
Joel Greenblatt 2017-06-30 New Buy0.01%$5.55 - $7.04 $ 5.20-17%55,639
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:TSE:7774, SZSE:002898, LSE:PRTC, NAS:SRNE, NAS:CMTA, XSWX:MOLN, NAS:ADRO, NAS:ARWR, ROCO:4157, NAS:ACRS, NAS:CASI, NAS:CDXS, OSTO:ONCO, NAS:CASC, NAS:AKAO, NAS:FPRX, NAS:ODT, XPAR:STAGR, NAS:FATE, XKRX:141080 » details
Traded in other countries:KYX.Germany,
Headquarter Location:USA
Keryx Biopharmaceuticals Inc focuses on developing medicines to people with kidney diseases. The marketed product of the company is auryxia tablet, which is a iron based medicine.

Keryx Biopharmaceuticals Inc focuses on developing medicines to people with kidney diseases. The marketed product of the company is auryxia tablet, which is a iron based medicine.

Top Ranked Articles about Keryx Biopharmaceuticals Inc

Keryx Biopharmaceuticals Announces First Quarter 2018 Financial Results
Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2018 Financial Results on Thursday, May 10, 2018
Keryx Biopharmaceuticals Announces Changes to Management and Preliminary First Quarter 2018 Revenue
Seth Klarman Dives Into Orexigen in Wake of Sale Beleaguered pharmaceutical company is being acquired for $75 million
Baupost Group’s Seth Klarman (Trades, Portfolio) disclosed this week he plunged into floundering pharmaceutical company Orexigen Therapeutics Inc. (OREX) on April 13, buying over 7 million shares. Read more...
Keryx Biopharmaceuticals Announces Late-breaking Ferric Citrate Abstract Accepted for Presentation at the 55th ERA-EDTA Congress
Keryx Biopharmaceuticals Receives 2018 Corporate Innovator Award from the National Kidney Foundation
Keryx Biopharmaceuticals Announces Publication of Data from the Phase 3 Trial of Auryxia® (ferric citrate) for Iron Deficiency Anemia in Patients with Chronic Kidney Disease, Not on Dialysis, in the American Journal of Hematology
Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results
Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 7, 2018
Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 7, 2018

Ratios

vs
industry
vs
history
PS Ratio 8.64
KERX's PS Ratio is ranked higher than
56% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. KERX: 8.64 )
Ranked among companies with meaningful PS Ratio only.
KERX' s PS Ratio Range Over the Past 10 Years
Min: 1.18  Med: 37.6 Max: 2228
Current: 8.64
1.18
2228
EV-to-EBIT -6.78
KERX's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. KERX: -6.78 )
Ranked among companies with meaningful EV-to-EBIT only.
KERX' s EV-to-EBIT Range Over the Past 10 Years
Min: -29.7  Med: -5.7 Max: 54.6
Current: -6.78
-29.7
54.6
EV-to-EBITDA -6.86
KERX's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. KERX: -6.86 )
Ranked among companies with meaningful EV-to-EBITDA only.
KERX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -29.7  Med: -5.7 Max: 53.7
Current: -6.86
-29.7
53.7
EV-to-Revenue 9.76
KERX's EV-to-Revenue is ranked higher than
56% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. KERX: 9.76 )
Ranked among companies with meaningful EV-to-Revenue only.
KERX' s EV-to-Revenue Range Over the Past 10 Years
Min: -7.3  Med: 32.6 Max: 1705.9
Current: 9.76
-7.3
1705.9
Current Ratio 2.66
KERX's Current Ratio is ranked lower than
60% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. KERX: 2.66 )
Ranked among companies with meaningful Current Ratio only.
KERX' s Current Ratio Range Over the Past 10 Years
Min: 1.88  Med: 6.74 Max: 106.93
Current: 2.66
1.88
106.93
Quick Ratio 1.87
KERX's Quick Ratio is ranked lower than
64% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. KERX: 1.87 )
Ranked among companies with meaningful Quick Ratio only.
KERX' s Quick Ratio Range Over the Past 10 Years
Min: 1.87  Med: 6.74 Max: 106.93
Current: 1.87
1.87
106.93
Days Inventory 291.61
KERX's Days Inventory is ranked lower than
85% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. KERX: 291.61 )
Ranked among companies with meaningful Days Inventory only.
KERX' s Days Inventory Range Over the Past 10 Years
Min: 244.72  Med: 833.58 Max: 2886.82
Current: 291.61
244.72
2886.82
Days Sales Outstanding 66.66
KERX's Days Sales Outstanding is ranked higher than
63% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. KERX: 66.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
KERX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 28.12  Med: 54.39 Max: 97.55
Current: 66.66
28.12
97.55
Days Payable 135.88
KERX's Days Payable is ranked higher than
63% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. KERX: 135.88 )
Ranked among companies with meaningful Days Payable only.
KERX' s Days Payable Range Over the Past 10 Years
Min: 19.96  Med: 94.4 Max: 463.34
Current: 135.88
19.96
463.34

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.70
KERX's 3-Year Average Share Buyback Ratio is ranked higher than
63% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. KERX: -8.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
KERX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -34.8  Med: -11.7 Max: -6.3
Current: -8.7
-34.8
-6.3

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.23
KERX's Price-to-Median-PS-Value is ranked higher than
93% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. KERX: 0.23 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
KERX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 2.15 Max: 138.91
Current: 0.23
0
138.91
Earnings Yield (Greenblatt) % -14.62
KERX's Earnings Yield (Greenblatt) % is ranked lower than
67% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. KERX: -14.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
KERX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -77911.5  Med: -11.4 Max: 27616.5
Current: -14.62
-77911.5
27616.5

More Statistics

Revenue (TTM) (Mil) $70.57
EPS (TTM) $ -1.40
Beta2.65
Volatility35.70%
52-Week Range $3.92 - 8.38
Shares Outstanding (Mil)120.44

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 89 138 183
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.64 -0.16 0.12
EPS without NRI ($) -0.64 -0.16 0.12
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}